A FTSE 100 Global Pharma is using the P3MO platform across multiple business functions and projects, including managing a product launch requiring FDA approval. Within three months of going live, the team had achieved over $1.4m in quantifiable savings. The need for management review meetings was reduced significantly, risks are reviewed and managed on the platform, not re-litigated in the room. The platform has encouraged collaborative working with project colleagues from a global team and 3rd-party providers, culminating in more organic and positive discussions and driving decisions in real time. The key win was identification of critical milestone that would have caused a 5-month delay to FDA approval, negatively affecting go to market deadlines reducing revenue opportunity by millions of dollars.
